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Rubella virus (RuV) has recently been found in association with granulomatous
inﬂammation of the skin and several internal organs in patients with inborn errors of
immunity (IEI). The cellular tropism and molecular mechanisms of RuV persistence and
pathogenesis in select immunocompromised hosts are not clear. We provide clinical,
immunological, virological, and histological data on a cohort of 28 patients with a broad
spectrum of IEI and RuV-associated granulomas in skin and nine extracutaneous tissues
to further delineate this relationship. Combined immunodeﬁciency was the most frequent
diagnosis (67.8%) among patients. Patients with previously undocumented conditions,
i.e., humoral immunodeﬁciencies, a secondary immunodeﬁciency, and a defect of innate
immunity were identiﬁed as being susceptible to RuV-associated granulomas.
Hematopoietic cell transplantation was the most successful treatment in this case
series resulting in granuloma resolution; steroids, and TNF-a and IL-1R inhibitors were
moderately effective. In addition to M2 macrophages, neutrophils were identiﬁed by
immunohistochemical analysis as a novel cell type infected with RuV. Four patterns of
RuV-associated granulomatous inﬂammation were classiﬁed based on the structural
organization of granulomas and identity and location of cell types harboring RuV
antigen. Identiﬁcation of conditions that increase susceptibility to RuV-associated
granulomas combined with structural characterization of the granulomas may lead to a
better understanding of the pathogenesis of RuV-associated granulomas and discover
new targets for therapeutic interventions.
Keywords: inborn errors of immunity, primary immunodeﬁciency, vaccine-derived rubella viruses, granulomatous
inﬂammation, skin lesion, neutrophils, macrophages, granuloma treatments

vascular ﬁbroblasts, the ciliary body of the eye, and in
placental capillary endothelium correlate with organ
abnormalities in this syndrome (9, 10). Other less common
pathologies caused by persistent wild type RuV infection
include rubella encephalitis, Fuchs’ uveitis, arthralgia, and
arthritis (11–14).
Several cases of IEI with granuloma formation have recently
been identiﬁed in association with RuV vaccine strain RA27/3
(15–20). Infectious immunodeﬁciency-related vaccine-derived
rubella viruses (iVDRV) were isolated from granuloma
biopsies and sequenced (16, 20). The iVDRV genomes
contained multiple mutations which resulted in viruses with
altered growth properties compared to the parental vaccine
strain: iVDRV strains were less cytopathic, produced less
infectious virus and could establish long-term persistent
cultures in primary human ﬁbroblasts (20). Patients with IEI
develop rubella-associated granulomas from weeks to decades
after MMR vaccination (18). The recent report of a patient with
common variable immunodeﬁciency (CVID) with wild type RuV
associated granulomas presenting in his 70s provides the ﬁrst
evidence that, in addition to vaccine virus strain, wild type RuV
strains are also capable of long-term asymptomatic persistence
and clinical re-emergence as symptomatic granulomas decades
later (21). The cellular or tissue reservoir for latent iVDRV and
wild type RuV, the mechanism of virus persistence, and the cause
of virus-associated lesions in different organs is presently
unknown. The risk factors and clinical manifestations remain
incompletely described.

INTRODUCTION
Inborn errors of immunity (IEI) are a heterogeneous group of
more than 450 monogenic disorders affecting different
components of the immune system and manifesting with
increased susceptibly to autoinﬂammation, autoimmunity,
atopy, infection, bone marrow failure, and/or malignancy (1,
2). Chronic infection in patients with IEI can trigger formation of
histopathological immune structures around antigens, resulting
in granulomas, which primarily consist of macrophages and
lymphocytes (3). If the immune system fails to clear the
antigen, granulomas themselves can become a signiﬁcant
pathology with damage to the affected organ. The estimated
prevalence of all types of granulomas (both sterile and nonsterile) in individuals with IEI is 1-4% (4). Effective treatment of
granulomatous inﬂammation depends on correct identiﬁcation
of the combined immunological and microbial etiology, and
often presents a diagnostic and therapeutic challenge for
clinicians and pathologists (5).
Rubella virus (RuV) is a single-stranded positive sense RNA
virus from the Matonaviridae family. Both wild type RuV and
the live-attenuated vaccine strain RA27/3, which is part of the
MMR vaccine used in most countries, can cause persistent
infection resulting in several associated pathologies (6).
Persistent infection of the developing fetus with wild type RuV
often results in an array of developmental abnormalities known
as congenital rubella syndrome (7, 8). Detection of RuV antigen
in brain progenitor cells, alveolar macrophages, cardiac and
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biopsy pathologies, granuloma treatments and outcomes. The
survey was completed between January 2021 and March 2021.

Cutaneous granulomas are the most frequent manifestation
diagnosed, but other organs including the liver, spleen, and lungs
can also be affected (4, 22, 23). RuV antigen is localized in M2
macrophages at the center of the granulomas in previously
described cases (16, 17, 24, 25), but a detailed description of
the spatial organization of RuV associated granulomas and its
cellular constituents is lacking.
Here, we examine RuV-associated granulomas from 28
patients with inborn and acquired errors of immunity to
determine whether speciﬁc inﬂammatory patterns localize to
certain tissue sites or are associated with clinical characteristics.
We present immunohistochemical evidence that macrophages
and neutrophils play a role in deﬁning RuV-associated
granulomatous patterns in inﬂamed tissues. Serological and
molecular data are analyzed to determine whether patients
develop an efﬁcient anti-rubella humoral immunity and whether
RuV persisting in these patients are vaccine derived. The
characterization of different patterns of inﬂammation in RuVassociated granulomas may lead to a better understanding of the
role of RuV in chronic tissues inﬂammation and associated
pathologies and identify new targets for therapeutic interventions.

Fluorescent Immunohistochemical
Staining (IHC) and Imaging
The presence of rubella antigen in FFPE tissue sections was
detected by ﬂuorescent IHC using mouse monoclonal antibody
against rubella virus capsid (RVC) (Abcam, cat# ab34749) as
previously described in detail (16). RuV-infected cell types were
determined by double immunostaining with either rabbit
monoclonal antibodies against CD3 (Abcam, cat# ab16669),
CD14 (Abcam, cat# ab133335), CD20 (Abcam, cat# ab78237),
CD34 (Abcam, cat# ab254022), CD68 (Cell Signaling, cat#
76437), CD163 (Abcam, cat# ab 182422), CD71 (Abcam, cat#
ab108985), myeloperoxidase (MPO) (Abcam, cat# ab208670), or
rabbit polyclonal antibody against CD206 (Abcam, cat#
ab64693), and von Willebrand Factor (vWF) (Sigma, cat#
F3520). FFPE tissue sections of normal human brain, lymph
node, pancreas, spleen, lung, skin, colon, kidney, and liver
(Newcomer Supply, Middleton, WI) were used as normal
tissue controls. Mouse monoclonal antibodies against measles
n u c l e o p r o t e i n (M i l l i p o r e , c a t # M A B 8 9 0 6 ) , m u m p s
nucleoprotein (Abcam, cat#ab9880), or mouse monoclonal
antibody cocktail against varicella zoster virus were used as
negative controls for granuloma staining. IHC stain was
visually scored as follows based on the number of RVC+ cells
and intensity of RVC immunostaining: 1=weak, 2=moderate,
3=strong, 4=very strong. Images were acquired using either a
Zeiss epiﬂuorescence microscope AxioImager.A1 or a Zeiss laser
scanning confocal microscope LSM-800 (Carl Zeiss Microscopy,
LLC). To image large tissue sections, multiple overlapping ﬁelds
were acquired and stitched using a ZenBlue v3.3 software (Carl
Zeiss Microscopy, LLC).

MATERIALS AND METHODS
Ethics Statement
Diagnostic samples were obtained from all patients as a part of
clinical care with provision of informed consent by attending
physicians. Samples were submitted to the Rubella Laboratory
(Centers for Disease Control and Prevention (CDC), Atlanta,
USA) for molecular testing, virus culture, and rubella serology.
Testing was performed as a part of the reference and surveillance
responsibilities of the CDC laboratory. Since RuV analyses were
conducted for the purpose of public health response, this work
was determined not to be research in humans by the CDC
Institutional Review Board (IRB). Types of specimens collected
for diagnostic purposes are indicated in Table 1 for each patient.
Archived formalin-ﬁxed parafﬁn-embedded (FFPE) specimens
were tested by the CDC laboratory with nondisclosure of patient
information, which was determined to be ethically acceptable by
the CDC IRB. This work was determined to be non-applicable
for human subject regulations (project determination numbers
P_2017_DVD_Icenogle_415 and P_2017_DVD_Icenogle_330).

RuV Molecular Analysis
Viral RNA isolation, RuV RT-PCR, viral RNA sequencing and
phylogenetic analysis have been described previously (20).

Rubella Serology
Rubella IgM and IgG testing was performed with a Rubella IgM
Capture EIA Kit (Diamedix, Miami, FL) and ZEUS ELISA
Rubella IgG Test System (ZEUS Scientiﬁc, Branchburg, NJ).
RuV neutralization assay was performed as previously
described (20). The neutralization titer (NT50) of a serum
sample was expressed as the reciprocal of the dilution of the
serum that neutralized 50% of added RA27/3 vaccine
virus strain.

Patient Survey of Clinical and
Immunological Characteristics
Patients with granulomas of unknown etiology were identiﬁed
through a network of colleagues and personal communications.
A 22-question survey was designed by Kathleen E. Sullivan and
administered to 24 physicians attending immunodeﬁcient
patients with granulomas to assess the following: patient
current age and age of IEI manifestation and diagnosis, IEI
genetic cause, mean CD3 and naïve CD3 counts, chronic
infections and autoimmunity, age at MMR, age at granuloma
onset, granuloma locations at onset, organs involved in
inﬂammation, age at granuloma biopsy and description of
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RESULTS
Characteristics of the Patient Cohort
We identiﬁed 28 patients with inborn and acquired errors of
immunity with RuV+ granulomatous inﬂammation in one or
more organs. Table S1 summarizes clinical, immunological, and
genetic characteristics of the patients. Six patients (21%) are
deceased due to various co-morbidities.
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TABLE 1 | Rubella virus testing of clinical samples from 28 IEI patients.
Pt
#

Age (years)
at
Sampling

1

15
16
16
17

FFPE skin, ﬁnger, old lesion
FFPE liver
FFPE skin, ﬁnger, new lesion
serum

17
17
18
18
18
18
18
18
18
18
18
18
5
5
5
59
59
3
3
11
12

skin biopsy, R index ﬁngerf
skin biopsy, R index ﬁnger, after 6 wks NTZg
skin biopsy, R index ﬁnger, after 3.5 months
NTZ
lymph node, autopsy
tumor, arm, autopsy
elbow synovial tissue, autopsy
wrist synovial tissue, autopsy
normal skin, arm, autopsy
nerve tissue, autopsy
elbow joint ﬂuid, autopsy
wrist joint ﬂuid, autopsy
bone marrow aspirate, autopsy
FFPE skin 1
FFPE skin 2
NP swab
FFPE skin 1
FFPE skin 2
FFPE skin
FFPE bone marrow core
FFPE skin
serum

12
2
2
7
74
14
14
14
6
13
24
24
24
20
20
27
37
12
12
12
12
12
12
12
4
4
1.6
1.6
1.6
32
32

NP swab
FFPE GI biopsy
FFPE bone marrow clot
FFPE skin
FFPE skin
FFPE bone marrow core
FFPE liver
FFPE lung
FFPE left axillary lymph node
FFPE groin tissuei
FFPE bone marrow clot
FFPE bone marrow core
FFPE brain
FFPE liver
serum
FFPE skin
FFPE skin
FFPE skin
FFPE bone marrow core
FFPE bone marrow clot
FFPE GI biopsy 1
FFPE GI biopsy 2
whole blood
NP swab
skin biopsy
FFPE skin
FFPE skin
skin biopsy
serum
FFPE skin, leg right lateral
FFPE skin, arm, left upper

2

3
4
5

6
7
8
9

10
11
12

13
14
15
16

17
18

19

Tissue

IHC
Scorea

Granuloma
Patternb

P 1+
P 4+
P 1+

M-type
M-type
M-type

P 3+
P 2+

M(n) -type
M(n) -type

P 1+
Neg
P 1+
P 1+
P 2+

N-type

Real-Time
RT-PCR
(RuV Genotype)c

Virus
Isolationd

Neg

Neg

P (iVDRV)
P (iVDRV)
P (iVDRV)

P
P
P

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Ph
Neg

Neg
Neg
Neg
Neg
Neg
Neg

Neg

Neg

Rubella Serology

IgM-, IgG+, NT50 =
9200e

M-type
M-type
M-type
IgM-, IgG+; NT50 =
6400
P (iVDRV)

Neg
P 1+
P 3+
P 3+
1+
Neg
P 1+
P 1+
P 4+
P 4+
P 3+
P 1+
P 2+

Neg

N-type
N-type

DNI-type
N-type

DNI-type
M-type
IgM+, IgG+

P 3+
P 3+
P 4+
Neg
P1+
P 4+
P 2+

M-type
M-type
M-type

DNI-type
DNI-type

P1+
P 1+
P 4+

M-type
M-type
M(n) -type

Neg
P (iVDRV)
Neg

IgM-, IgG+
Neg
Neg

P (iVDRV)
IgM+ (grey zone), IgG+
P 2+
P 2+

M-type
M-type
(Continued)
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TABLE 1 | Continued
Pt
#

20

21
22
23
24

25
26
27
28

Age (years)
at
Sampling
33
37
38
38
38
38
11
11
11
11
2
2
11
4
4
1.4
1.4
5
5
5
5
5
5
5
5
5
5
5
12
19
3.8

Tissue

IHC
Scorea

Granuloma
Patternb

P 4+
P 1+

M-type
M-type

FFPE skin, arm, left upper
FFPE skin, arm, left upper
NP swab
urine
skin biopsy
serum
FFPE skin
FFPE bone marrow core
NP swab
whole blood
FFPE skin, left thigh
FFPE bone marrow core
FFPE skin, R index ﬁnger
FFPE skin 1
FFPE skin 2
FFPE skin 1
FFPE skin 2
FFPE brain, autopsy
FFPE myocardium, autopsy
FFPE kidney, autopsy
FFPE adrenal, autopsy
FFPE ovary, autopsy
FFPE lymph node, autopsy
FFPE colon, autopsy
FFPE lung, autopsy
FFPE skeletal muscle, autopsy
FFPE pancreas, autopsy
FFPE hippocampus, autopsy
FFPE skin, hand
FFPE spleen
FFPE brain
FFPE skin
serum
skin biopsy

P 4+
Neg

Real-Time
RT-PCR
(RuV Genotype)c

Virus
Isolationd

Neg
Neg
Neg
Neg

Neg

P (iVDRV)

Neg

Rubella Serology

Neg
IgM-, IgG+; NT=1280

N-type

IgM+, IgG+; NT=400
P 4+
P 4+
P 3+
P 4+
P 3+
P 4+
P 4+
1+
Neg
Neg
Neg
Neg
Neg
Neg
P 2+
Neg
P 1+
Neg
P3+
P1+
P3+
P4+

N-type
M-type
M(n)-type
M(n)-type
M-type
M-type

P (iVDRV)

Neg
Neg

DNI-type
DNI-type
M(n) -type
DNI-type
DNI-type
M(n) -type
IgM-, IgG+
Ph

Positive (P) IHC staining for RuV capsid was scored on a scale from 1+ to 4+ based on the intensity of staining and a number of positively stained cells. Neg – negative.
Granuloma pattens based on double IHC staining for RVC and cell type markers.
c
RuV RT-PCR was resulted either positive (P) or negative (Neg). RuV genotype was determined by sequencing and indicated in parentheses.
d
Virus isolation was done using Vero cells, P -positive, Neg- negative.
e
NT50– RuV neutralization titer.
f
Virus isolation and sequencing were previously reported for this biopsy sample collected prior to NTZ treatment (20).
g
NTZ – nitazoxanide treatment. A manuscript is currently in preparation to describe RuV RNA quantitation in the pre- and post-treatment biopsies, the comparison of the genomic
sequences and quasispecies composition of the viruses isolated pre- and post-treatments, and sensitivities of the recovered viruses to NTZ.
h
Not sufﬁcient material for sequencing.
i
This tissue was collected during the failed attempt to collect biopsy of the groin lymph node.
a

b

Underlying Inborn and Acquired Errors
of Immunity

there were four patients with atypical severe combined
immunodeﬁciency (aSCID) and two patients with DiGeorge
syndrome (22q11 deletion syndrome). Additionally,
there were two patients with CVID, one patient with Xlinked agammaglobulinemia (XLA), three patients with
hemophagocytic lymphohistiocytosis (HLH), one patient with
a defect of innate immunity (i.e., biallelic STAT1 loss-offunction), one patient with a secondary immunodeﬁciency
(lymphopenia), most likely due to severe malnutrition, and one
patient with an IgG2 and IgA deﬁciency without a genetic
explanation. The median age of immunodeﬁciency
manifestation was 2 years (age range 0-59 years). The genetic

The underlying immunodeﬁciencies were categorized according
to the International Union of Immunologic Societies (IUIS)
classiﬁcation (1, 2) (Table S1 and Figure 1A). The most
frequent phenotype, combined immunodeﬁciency (CID), was
found in 19 (67.8%) cases, and all were characterized by reduced
CD3 T-cell counts, 16 had a genetic diagnosis, and 8 had
phenotyping of naïve/memory T cells available showing loss of
naivety. Two CID patients (P3 and P23) were without a genetic
diagnosis and without naïve T-cell counts but had T-cell
lymphopenia and opportunistic infections. Within this group,
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A

B

D

E

C

F

FIGURE 1 | Characteristics of the patient cohort. Underlying immunodeﬁciencies (A). Genetic causes (B). Frequency of chronic infections (C). Organs involved in
inﬂammation (D). Granuloma location at onset (E). Age of the patients at the granuloma onset by the IEI type (F).

cause of IEI was determined for 21 (75%) cases at median age of 5
years (age range 0-37 years). The syndromic CID ataxia
telangiectasia with mutations in the ATM gene was the most
common single etiology found in four patients (Table S1
and Figure 1B).

MMR Vaccination
The ﬁrst dose of MMR vaccine was given to 22 (78.6%) patients
at a median age of 1 year (age range 0.8 – 2.5 years). P3 was
vaccinated but the vaccination date is unknown. P7 was not
vaccinated but community transmission of wild type RuV was
documented. The vaccination status of four patients (P12, P14,
P15, P19) is unknown. The second MMR dose was given to 13
(46.4%) patients at a median age of 2.5 years (age range 1.25 –
5.25 years). Except P26, 21/22 (95.5%) individuals were
vaccinated prior to an IEI diagnosis.

Clinical and Immunologic Phenotypes
Respiratory tract infections were the most frequently observed
infections; the most common infectious agents identiﬁed were
Epstein-Barr Virus (EBV), cytomegalovirus (CMV), and
mycobacteria (Figure 1C and Table S1). Different organs were
involved in granulomatous disease manifestations with skin,
liver, and lymph node being the most frequent (Figure 1D and
Table S1). Granulomas were initially identiﬁed in the inﬂamed
tissues after H&E staining of the tissue biopsies. There were
multiple locations of granulomas at disease onset; cutaneous
granulomas were the most frequent ﬁrst presentation (Figure 1E
and Table S1). Patient 4 (P4), P8, and P27 had granulomas
located in multiple organs at disease onset; bone marrow
granulomas were found in all these three cases (Table S1). The
overall median age at granuloma onset was four years (age range
1 to 59 years) and appeared to depend on the IEI type. For
instance, patients with HLH (P5, P17, P18) developed
granulomas soon after vaccination while patients with CVID
(P9, P19) developed granulomas later in life (Figure 1F and
Table S1). The course of the disease was complicated by end
organ damage in several patients (Table S1). Low CD3+ T-cell
counts (<1,600 cells/µl) were detected in 23/28 (82.1%) patients.

Frontiers in Immunology | www.frontiersin.org

Detection and Sequencing of RuV RNA
Fresh frozen skin samples were collected from ﬁve (17.9%)
patients. P1, P18, P28 biopsies (60%) were tested positive for
the presence of RuV RNA by RT-PCR (Table 1). RuV was not
detected in the unﬁxed skin biopsies of P17 and P19 by RT-PCR
even though the other skin biopsies of these patients were
positive by IHC; this could reﬂect a sampling problem as RuV
is not distributed evenly in the lesions. Multiple tissue samples of
P1 were tested. All three skin biopsies collected prior and after
nitazoxanide therapy were positive by RT-PCR and cell culture,
thus conﬁrming the failure to clear RuV cutaneous infection by
this treatment. One sample (wrist joint ﬂuid) out of nine
collected after upper limb amputation of P1 was also RuV+ by
RT-PCR. Nasopharyngeal swabs were available for ﬁve (17.9%)
patients, and three of these (60%) were RuV+ by RT-PCR but no
live virus was recovered. We were able to amplify the RuV
genotyping fragment from RNA isolated from P22 FFPE skin
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tissue in one out of three (33%) available for analysis. Sequencing
conﬁrmed the presence of iVDRVs in six out of seven (85.7%)
PCR-positive cases. A genotype of RuV (wild type or iVDRV) in
lesions of other patients was not determined.

Granuloma Characteristics by
Immunoﬂuorescent
Immunohistochemistry
A total of 60 FFPE tissue blocks from 28 patients were available
for analysis. The presence of RuV capsid protein (RVC) in 27
skin samples and 33 other tissues was detected by ﬂuorescent
immunohistochemistry (IHC) (Table 1). To determine the cell
composition and spatial organization of the granulomas, all
slides were double stained for RVC and either for CD206 (M2
macrophage marker) or MPO (cytoplasmic neutrophil marker).
Selected slides were also double stained for RVC and CD68 (panmacrophage), CD163 (a marker for M2 macrophage subset,
which only partially overlaps with CD206+ M2 macrophage
subset), CD3 (T cells), CD14 (monocytes), CD20 (B cells),
CD34 (stem cells), CD71 (erythroid precursors), vWF
(endothelial cells). As a negative control, the slides were
stained with antibodies to other live-attenuated vaccine viruses,
i.e., measles, mumps, or varicella zoster virus. Granulomas on all
slides were negative for these control viral antigens (not shown).

RuV Serological Findings
Rubella serology was performed for eight (28.6%) patients
(Table 1). Three (37.5%) patients (P1, P13, P20) had persistent
RuV IgM antibody. All four patients, for which RuV neutralization
assay was done, had NT50 titers of RuV neutralizing antibody
ranging from 400 to 9,200, which were substantially higher than
typically found in immunologically normal vaccinated individuals
(NT50<100). These data were consistent with previously reported
ﬁndings (20) and substantiate the proposition that high levels of
RuV neutralizing antibodies can potentially serve as a marker of
persistent rubella infection in individuals with IEI.

Therapeutic Efforts and Outcomes
Various therapies were implemented (Table 2). Supportive
treatments, such as antimicrobials, antifungals, and IgG
supplementation, did not result in relevant improvement.
Steroids and disease modifying antirheumatic drugs (DMARDs)
provided some resolution of inﬂammation in several cases.
Treatments with biologicals, such as TNF-a and IL-1R
antagonists led to reduction of lesions in 3/5 (60%) patients.
Curative treatment for immunodeﬁciency (hematopoietic cell
transplantation) resulted in resolution of the lesions in those
patients (5 of 7) who survived the procedure.

Cutaneous Granulomas
RVC+ granulomas were detected in skin biopsies of all 20 patients
who had cutaneous lesions. Multiple skin biopsies were available for
six patients; 5/6 patients had all sites positive for RVC, and one
patient (P3) had a single RVC+ biopsy site out of two sites tested.
Skin biopsies of 15/20 (75%) patients contained well-formed
epithelioid granulomas. These granulomas were either nonnecrotizing (10/15) or necrotizing (5/15).

TABLE 2 | Treatment response in 28 patients with granulomas.
Treatments
Antibiotics
Antifungals, topical or
oral
Steroids, oral
Steroids, topical

Patient #
2, 6, 16, 18
2, 4, 6, 16,17
8, 9, 10, 12, 16,17, 20, 24
2, 3, 4, 8, 18, 21, 24, 28

We use as the designation for non-necrotizing granulomas with a
clearly deﬁned central core of interconnected RVC+CD206+ M2
macrophages with epithelioid morphology (Figures 2A, F, 3A).
RVC antigen was diffusely distributed in the cytoplasm of these
macrophages. RVC+CD206+ Langhans giant cells were present
in the granuloma cores of ﬁve patients (P3, P14, P15, P16, and
P19) (Figure S1). A CD163+ M2 macrophage subset with a small
number of RVC+ cells was peripherally located (Figure 2B).
Some RVC + M2 macrophages in granuloma cores were
CD206 high CD163 low double positive. Abundant CD14 +
monocytes were also present in M-type granulomas, and
monocytes adjacent to RVC+CD206+ foci were often positive
for RVC (Figure 2C). Variable but usually small numbers of
MPO+ neutrophils were randomly distributed in the M-type
granuloma centers among the RVC+ macrophages; most of them
were negative for RVC (Figure 2D, 3A). None of the numerous
CD3+ T cells stained positive for RVC. T cells were randomly
distributed throughout the granulomas; some of them were in
close contact with RVC+ macrophages (Figures 2E, 3A). Only a
small number of CD20+ B cells were localized at the periphery of
all granuloma types (not shown).

no effect
no effect

Steroids, intralesional
IVIG
DMARDs
(mycophenolate mofetil,
hydroxychloroquine,
methotrexate)
IL-1R antagonist
(anakinra)
TNF-a antagonist
(etanercept,
adalimumab, inﬂiximab)
Anti-CD20 (rituximab)
IL-1 beta antagonist
(canakinumab)
CD80/CD86 antagonist
(abatacept)
Nitazoxanide

8
10, 16, 17, 18, 21, 24, 28
3, 9, 17,19, 27

1/8 improvement (P8)
2/8 improvement (P3,
P18)
no effect
no effect
1/5 improvement (P19)

7, 27

1/2 improvement (P7)

1, 4, 19

2/3 improvement (P4,
P19)

Hematopoietic cell
transplantation

7, 12, 16, 18, 20, 24, 28

9, 10, 24, 27
17

no effect
no effect

23

no effect

1, 18

M-Type RuV-Associated Granuloma

Outcomes

1/2 fewer new lesions
(P18)
5/7 granulomas
resolved, P20 and P24
did not survive the
procedure

M(n)-Type RuV-Associated Granuloma
We use as the designation for necrotizing epithelioid granulomas
consisting of a ring of RVC + CD206 + M2 macrophages
surrounding acellular necrotic centers (Figures 3B–D). M(n)-

IVIG, intravenous immunoglobulins; DMARDs, disease modifying antirheumatic drugs.
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FIGURE 2 | A structure of M-type RuV-associated cutaneous granuloma and its cellular elements. Histological double immunoﬂuorescent staining of sequential
tissue sections (P18) for RVC (red) and one of the cell type markers (green) shows the presence of RVC predominantly in CD206+ M2 macrophages (A) and
infrequently in CD163+ M2 macrophages (B), CD14+ monocytes (C) and in sporadic MPO+ neutrophils (D). Layers of many RVC- CD3+ T cells surround RVC+/
CD206+ granuloma centers (E). Scale bar: 200 µm. Schematic of M-type RuV-associated granuloma pattern (F).

type granulomas often contained a mixture of necrotizing and
non-necrotizing granulomas in a single biopsy each likely being
different stages of granuloma development. Densely packed
CD3+ T cells and some neutrophils were present between the
ring of RVC+CD206+ macrophages and necrotic centers. The
necrotic centers contained cell debris that were strongly stained
for MPO and CD3 (Figures 3B, C). Weak punctuate staining for
RVC and CD206 was also detected in the necrotic centers
(Figure 3C). These data suggest that T cells and neutrophils
migrated into granulomas, participated in the destruction of RuV
infected macrophages and died by necrosis thus forming necrotic
centers of M(n)-type granulomas. Monocytes and CD163+ M2
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macrophage were abundant and their distribution in M(n)-type
granulomas was like those in M-type granulomas.

N-Type RuV-Associated Granuloma
We use as the designation for necrotizing neutrophilic
granulomas with neutrophils being the main cell type
harboring RuV antigen (Figure 4). The skin biopsies of 5/20
(25%) patients (P3, P7, P8, P20, P21) contained N-type
granulomas. The cores of these granulomas consisted of many
tightly packed MPO+RVC+ neutrophils and were devoid of other
cell types (Figure 4A). There were also multiple areas of necrosis
in the core. Clusters of CD206+ M2 macrophages with infrequent
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FIGURE 3 | A progression of cutaneous granuloma from M-type to M(n)-type. Histological double staining of sequential tissue slides (P18) for either RVC (red)
and one of the cell type markers (green). Non-necrotizing M-type granuloma contains RVC+CD206+ M2 macrophages in the center with infrequent, mainly RVCneutrophils and abundant surrounding RVC-CD3+ T cells (A). Necrotizing M(n)-type granulomas with MPO+ and CD3 + staining of the necrotic centers surrounded
by RVC+CD206+ macrophages (B, C). Notice a rim CD3+ T cells located between acellular necrotic center and RVC+CD206+ macrophages (C). Scale bar: 100
µM. Schematic of M(n)-type RuV-associated granuloma pattern (D).

RVC+ cells were found adjacent to the N-type cores (Figure 4B).
Monocytes, CD163+ M2 macrophages and T cells were abundant
and distributed around the granuloma core (Figures 4C–F).
Visually determined RVC IHC positivity scores varied among
different biopsies of the same patient as well as among biopsies of
different patients. The IHC scores and granuloma types are listed
in Table 1. Notably, the granuloma patterns in individuals with
multiple biopsies did not change over time: multiple cutaneous
biopsies showed the same granuloma patterns, M-types in P1
and P19 or M(n)-types in P2 and P23. No correlation was
detected between the patterns of RuV-associated granulomas
and age of granuloma onset, age at granuloma sampling, and the
time elapsed between granuloma onset and sampling (Figure S2)
nor the IEI type or T-cell counts (Table S1),
IHC analysis of a newly developed skin lesion of P1 did not
reveal a clearly deﬁned granuloma (Figure 5). Instead, there was
an accumulation of several small clusters of RVC + M2
macrophages (10-50 cells each), which were localized under

Frontiers in Immunology | www.frontiersin.org

the epidermis. Each of these small macrophage clusters may
represent an early stage of granuloma formation. The skin biopsy
of an older lesion (not shown) and the liver biopsy (Figure S3) of
P1 contained typical M-type granulomas. This observation
suggests that RuV-infected macrophages could be a vehicle of
lateral dissemination of granulomas in the affected skin as
suggested for Mycobacteria-induced granulomas in
tuberculosis (26).

Granulomas in Extracutaneous Sites
Liver
The liver biopsies from 2/3 patients (P1, P13) had M-type RVC+
granulomas comparable with cutaneous M-type RVC +
granulomas. RVC antigen was detected in CD206 +
macrophages and multinucleated giant Langhans cells in the
granuloma centers and infrequent RVC+MPO+ neutrophils were
found in the surrounding areas (Figure S3).
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FIGURE 4 | A structure of N-type RuV-associated cutaneous granuloma and its cellular elements. Histological double immunoﬂuorescent staining of sequential
tissue sections of skin biopsy (P21) for RVC (red) and one of the cell type markers (green) shows predominant RVC staining of MPO+ neutrophils (A), infrequent RVC
staining of CD206+ M2 macrophages (B), CD163+ M2 macrophages (C), and CD14+ monocytes (D). Numerous RVC-CD3+ T cells surround the RVC+ neutrophil
core (E). Scale bars: 200 µm and 20 µm (inlet). Schematic of N-type RuV-associated granuloma pattern (F).

Gastrointestinal (GI) Tract

plasma membrane and RVC antigen localized in large globular
structures that most likely were phagosomes (Figure 6B). RVC+
neutrophils phagocytized by CD206+ macrophages were also
observed (Figure 6D).

GI biopsies were available for two patients: P2 had one RVC- GI
biopsy and P16 had two RVC+ GI biopsies. P16, who presented
with HLH, had sustained small jejunal perforations;
disseminated CMV and Histoplasma spp. infections were
identiﬁed in addition to RuV (Table S1). Predominant RVC+
cells were neutrophils (Figure 6A) and well-formed granulomas
with clearly deﬁned macrophage or neutrophil cores as present
in skin biopsies were not observed. We deﬁned DNI-type (diffuse
neutrophil inﬂammation) of RuV-associated granuloma as a
disorganized aggregation of abundant RVC + neutrophils
intermixed with macrophages (some RVC+) and RVC- T cells
(Figures 6B–D). CD206+RVC+ cells in DNI-type granulomas
were morphologically distinct from those in the centers of Mtype granulomas: rounded with shorter cell processes, not
interconnected, with CD206 protein localized mainly in the

Frontiers in Immunology | www.frontiersin.org

Brain
In brain biopsies, MPO+RVC+ neutrophils were found inside
capillaries, in perivascular regions, and near parenchymal
hemorrhage (P12, P24, P27) (Figures 7A, B). In addition, brain
biopsies of P12 and P27 with clinical encephalitis (Table S1)
contained several small granulomas with RVC-CD206+ M2
macrophage cores and RVC+ neutrophils intermixed with other
immune cells surrounding RVC- granulomas and throughout the
brain parenchyma (DNI-type granuloma). RVC+ neutrophil
inﬁltration was mild in the brain from P12, but severe, with
multiple arears of necrosis, in the brain of P27 (Figures 7C, D).
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FIGURE 5 | Biopsy of a newly developed cutaneous lesion (P1). Double histological immunoﬂuorescent staining shows small clusters of RVC+CD206+ M2
macrophages under the epidermis. Scale bars: 100 µm (top panel) and 20 µm (bottom panel).

CD68+ macrophages in the paracortex area (Figure S6).
Granuloma type was not deﬁned for this sample.

The pathology report for P12, with XLA and large granular
lymphocyte (LGL) disease on treatment with cyclophosphamide,
described perivascular cuffs of lymphocytes, neurophagia, and glial
nodules characteristic of viral infection. P27 with biallelic STAT1
loss-of-function had glial ﬁbrillary acidic protein (GFAP)
autoimmune encephalitis. These data suggest that, while RuV
infection may not be the initial trigger of inﬂammation in the
brain, the inﬂux of RVC+ neutrophils can bring additional antigen
to the site and exacerbate the inﬂammation.

Bone Marrow
Granulomas were detected in bone marrow samples of P4, P6,
P8, and P27 by H&E staining (Table S1). P4 core biopsy, the only
one available for RVC IHC staining, contained M-type RuVassociated granulomas and a small number of RVC+MPO+
neutrophils (Figure 8A). Pathological changes, such as
hypocellularity, focal ﬁbrosis, and lymphoid aggregates were
found in one bone marrow sample (P12); almost all
neutrophils in this sample were RVC+. No granulomas or sign
of inﬂammation were noted in bone marrow samples of P9, P16,
P20, and P21 (Table S1). Nonetheless, P9 core biopsy contained
sporadic RVC+MPO+ neutrophils and almost all neutrophils in
P21 bone marrow were RVC+ (Figure 8B). No RVC+ cells were
detected in P16 and P20 core biopsies, but the presence of
sporadic RVC+ neutrophils in P16 bone marrow clot suggested
either poor sampling or, more likely, uneven distribution of
infected neutrophils in bone marrow. Infrequent RVC+CD68+
macrophages and RVC+CD14+ monocytes were also detected in
bone marrow samples, while CD34+ stem cells and CD71+
erythroid precursors were RVC-negative (not shown). The
presence of RVC+ neutrophils in otherwise normal bone
marrow samples suggest that bone marrow is not a site of

Spleen
Numerous granulomas with RVC-CD206+ M2 macrophage
containing centers in the P26 spleen sample were surrounded
by RVC + neutrophils (DNI-type granuloma). Occasional
RVC+CD206+ M2 macrophages were also observed (Figure S4).

Lung, Pancreas
RVC + neutrophils were found randomly distributed in
parenchyma of the P9 lung biopsy and the P24 pancreas and
lung (DNI-type granuloma) (Figure S5). In other P24 autopsy
tissues, RVC+ neutrophils were detected only in lumens of
blood vessels.

Lymph Node
One of two available lymph node samples (P10) were RuV
positive. RVC+ cells were CD14+ monocytes and sporadic
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FIGURE 6 | A structure of DNI-type RuV-associated granuloma and its cellular elements. Histological double immunoﬂuorescent staining for RVC and either MPO
(A), CD206 (B, D), or CD3 (C) showing RVC+MPO+ neutrophils, RVC+CD206+ macrophages with globular RVC likely in a phagosome (yellow arrow) and abundant
RVC-CD3+ T cells in the inﬂamed GI tissue of P16 (A–C). RVC+ neutrophil phagocytized by CD206+ macrophage (D). Scale bars: 100 µm (A-C), 20 µm (inlets), and
2 µm (D). Schematic of DNI-type RuV- associated granuloma pattern (E).

aggregated RVC+ M2 macrophages. The newly identiﬁed pattern,
N-type of RuV-associated granulomas (25% of cutaneous
granulomas), was characterized by a predominance of RVC+
neutrophils with most of them organized in a compact core with
central necrosis. The fourth pattern of RuV-associated granulomas,
DNI-type, which prevails in extracutaneous lesions, was a poorly
organized granuloma characterized by diffuse inﬁltration of RVC+
neutrophils intermixed with monocytes, macrophages, and
lymphocytes. Overlapping or even novel patterns may be
identiﬁed as a number of characterized RuV-associated
granulomas grows.
There was no association between speciﬁc granuloma
patterns and the age of granuloma onset or the underlying
error of immunity. The characteristic feature of all granuloma
patterns was a substantial presence of T cells even though most
individuals had low T-cell counts or defective T-cell cytotoxicity.
Our analysis of the IHC images suggests that the spatial

RuV-associated inﬂammation but rather a persistence niche
for RuV.

DISCUSSION
Herein, we report the ﬁrst study of spatial and cellular organization
of RuV-associated granulomas in subjects with inborn and acquired
errors of immunity using ﬂuorescent immunohistochemical
staining of lesion biopsies. One of the key ﬁndings is that, in
addition to macrophages, neutrophils in granulomas contained
the RVC antigen. The large number of granuloma cases analyzed in
detail in this manuscript allowed identiﬁcation of four distinct
granuloma patterns, which were classiﬁed based on the identity of
cells harboring RVC antigen and their distribution in the lesions.
Most cutaneous granulomas (75%) were non-necrotizing M-type or
necrotizing M(n)-type, an epithelioid granuloma type with focally
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FIGURE 7 | RuV in brain neutrophils. Histological double immunoﬂuorescent staining for RVC (A–D) and either MPO (A, D), vWF (B) or CD206 (C), showing RVC+
neutrophils in the lumen of blood vessels, perivascular cuff, and around the area of hemorrhage (yellow arrows) in P12 brain (A, B). Numerous RVC+ neutrophils
surrounding RVC-CD206+ granuloma in P27 brain (C, D). Notice a colocalization of MPO granules with RVC (Dii). Scale bars: 20 µm (A, B, Ci, Di). 50 µm (C, D),
and 2 µm (Dii).

being by far the most common (21/80, 26%) although this disease
only constitutes 0.3%-8% in several national registries (28–33). Both
CVID patients in our cohort had low CD3+ T cells and a phenotype
supportive of abnormal T-cell function suggesting it was the T-cell
defect rather than the humoral deﬁciency that contributed to RuV
susceptibility. The genetic etiologies of the three HLH patients
reported here, and 12 patients recently reported by Gross et al,
which include the RAB27A, UNC13D, and PRF1 genes, impacted
CD8+ T-cell cytotoxicity (25). In addition, we report several
previously undocumented conditions responsible for increased
susceptibility to RuV -associated granulomas. DiGeorge
syndrome is a recognized T-cell deﬁciency, related to impaired
thymic T-cell production. The mechanism of susceptibility to RuV
in patients with humoral immune deﬁciencies (P11 with IgG2 and
IgA deﬁciencies) remains poorly understood as humoral immunity
is not considered as a major mechanism of immune control and
eradication of RuV in chronically infected individuals (20). P12
with XLA was being treated for his LGL with cyclophosphamide, a
possible contributor. Additionally, maturation, recruitment, and
function of macrophages and neutrophils depend on the Bruton’s
tyrosine kinase, BTK (34), thus providing a potential mechanism for
XLA patients. Although patients with STAT1 loss-of-function

organization of RuV associated granulomas does not prevent
close contact between T cells and infected macrophages and
neutrophils (Figure 3). This contrasts with TB granulomas in
which the spatial arrangement of cells limits the ability of T cells
to reach infected macrophages at the granuloma centers (27).
Other possibilities, such as T-cell exhaustion, limited generation
and/or recruitment of RuV-speciﬁc T cells, and generation of
RuV escape mutants, should be investigated to understand the
mechanisms of RuV persistence.
Only one pattern of RuV-associated inﬂammation in IEI
patients, M-type, has been previously described (16, 17, 25). The
reasons why we were able to identify additional patterns in this
study are the inclusion of individuals with diverse IEI types and the
relatively large size of the patient cohort. In addition to the
description of different granuloma patterns, this study also
provides extensive clinical information on 28 patients and
emphasizes the breadth of conditions where RuV should be
considered as a potential etiology of granulomatous
inﬂammation. On comparing with the published cases of RuV in
patients with IEI, few commonalities emerge (Table 3). Most
patients have T-cell quantitative and/or qualitative deﬁciency.
Various types of CID prevail (71%) with ataxia telangiectasia
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TABLE 3 | RuV-associated inﬂammation in IEI patients described in this case series and reported in the literature.
This case series
n=28

Perelygina et al. (16)
n=7

IEI type

CID (19)
HLH (3)
CVID (2)
Innate (1)
XLA (1)
Humoral (1)
Unknown (1)

CID (7)

Genetic cause

ATM (4)
22q11.2 del (2)
RAG1 (2)
RAG2
NBN
TAP1
TAP2
RAB27A
ADA
SLC7A7
UNC13D
POLE
RMRP
DCLRE1C
STAT1 (LOF)
BTK
No gene (7)

RuV location

Deceased

Neven et al.
(17)
n=9

Perelygina et al.
(20)
n=7

Buchbinder et al.
(18)
n=17

Gross et al.
(25)
n=12

CID (8)
CVID (1)

CID (7)

CID (16)
Neutrophil (1)

HLH 12/12

ATM (4)
No gene (3)

ATM (5)
RAG1
RAG2
PIK3CD
No gene (1)

ATM (3)
No gene (3)

ATM (5)
NBN (4)
LIG4
DCLRE1C
RMRP
RFXANK
CXCR4
CORO1A
IL2RG
No gene (1)

Rab27A (7)
UNC13D (3)
PRF (2)

Skin (20)
Bone marrow (6)
Brain (3)
Liver (2)
GI tract (1)
Lung (2)
Pancreas (1)
Lymph node (1)
Spleen (1)
Joint (1)

Skin (7)
Bone (1)

Skin (9)
Spleen (1)
Lymph node (1)

Skin (7)
Liver (2)
Bone (1)
Kidney (1)

Skin (17)

Skin (9)
Lung (2)
Liver (1)

6

4

Not reported

3

3

Not reported

CID (57, 71%)
HLH (15, 19%)
CVID (3, 4%)
Innate (1, 1%)
XLA (1, 1%)
Humoral (1, 1%)
Neutrophil (1, 1%)
Undetermined (1, 1%)
ATM (21)
RAB27A (8)
UNC13D (5)
NBN (5)
RAG1 (3)
RAG2 (2)
DCLRE1C (2)
RMRP (2)
CORO1A
LIG4
TAP1
TAP2
ADA
SLC7A7
POLE
BTK
RFXANK
CXCR4
PRF (2)
STAT1(LOF)
IL2RG
IKBKG
PIK3CD
Skin (69, 86%)
Bone marrow (6, 8%)
Liver (5, 6%)
Lung (4, 5%)
Brain (3, 4%)
Lymph node (2, 3%)
Spleen (2, 3%)
Kidney (1, 1%)
Bone (1, 1%)
Pancreas (1, 1%)
Joint (1, 1%)
GI tract (1, 1%)
16/59 (27%)

due to immunosuppression for immune dysregulation or other
etiology may play a role in triggering RuV emergence in adult
patients who had developed granulomas many years after
establishment of IEI diagnosis. Additional work to deﬁne innate,
monocyte, T-cell, and antibody responses may reveal new insights
into mechanisms of susceptibility to RuV persistence and
granuloma formation in different tissues.
Another important factor which allowed us to identify
multiple RuV-associated patterns was testing of a broad array
of tissues involved in inﬂammation. Patients with IEI and RuVassociated disease were primarily affected with cutaneous
granulomas (86%). This was the original phenotype described
(15, 16), and still constitutes the most common reason for
referral for testing. There is likely some ascertainment bias

mutations showed normal lymphocyte subsets and immunological
reactions, they were highly susceptible to infections due to the lack
of interferon responses, which were fundamental for the activation
of the pathogen killing pathways in infected macrophages (35).
Immunodeﬁciency in one patient (P6) was attributed to severe
malnutrition, which often leads to immune dysfunction (36). Thus,
susceptibility to RuV emergence from the tissue reservoir is likely
more complex than merely having a T-cell defect. However, our
data help to paint a somewhat clearer picture of the major
susceptibility factors. The patients generally produced excessive
amounts of RuV neutralizing antibodies and had some element of
T-cell dysfunction but were generally not categorized as having
SCID, which would have been a contraindication to immunization
with live viral vaccines. In addition, secondary immunodeﬁciency
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FIGURE 8 | RuV in bone marrow. Histological immunoﬂuorescent staining of bone marrow core biopsies of P4 (A) and P21 (B) for RVC (A, B) and either for CD206
(A) or MPO (B) shows the presence of RuV in M2 macrophages (A) and neutrophils (B). Scale bars: 20 µm (A) and 100 µm (B).

persistent infections is impeding thorough investigations of
antiviral strategies. The most common treatments were oral
and topical steroids which were moderately effective in some
patients in all case series. Consistent with other reports (18, 37), a
broad-spectrum antiviral drug nitazoxanide provided only mild
improvement. There have been responses in this case series to
TNF-a and IL-1R inhibitors, both are known suppressors of
myeloid-driven inﬂammation, suggesting that they offer some
ability to resolve lesions in patients with granulomatous
inﬂammation dominated by chronic neutrophil inﬁltration.
However, there were also patients in this series where these
same therapies failed. HCT was the most successful treatment,
which was performed in seven patients in this series with
resolution of the lesions in ﬁve successfully transplanted cases.
Lacking direct anti-viral agents that target RuV, there is clearly a
need for improved management of this subset of patients
with IEI.
The present study opens an intriguing possibility that the
bone marrow neutrophils or their myeloid precursors provide a
niche for long-term RuV persistence. There was notable presence
of RVC+ neutrophils in both normal and abnormal bone marrow
samples of 6/7 (86%) patients. The observation that the lesions

because the skin is more accessible to biopsy than other organs.
Nine extracutaneous tissues with RuV-associated granulomas
were described in this case series including three newly
recognized sites, i.e., bone marrow, brain, and GI tract
(Table 3). The observations that RuV-associated granulomas
can ﬁrst emerge in extracutaneous body sites often distant from a
vaccination site strongly argue against skin representing a unique
RuV reservoir. There were clear differences in the RuV
granuloma patterns in skin and extracutaneous locations. In
skin, the focal aggregates of RuV infected macrophages or
neutrophils most likely serve as the trigger for granuloma
assembly around them. In extracutaneous locations, RuV may
not be a major trigger of chronic inﬂammation but rather
exacerbates it as DNI-type granulomas with abundant RVC+
neutrophils were typically seen near areas of RuV-unrelated
inﬂammation, e.g., near RVC- granulomas in P16 GI, P26
spleen, and P27 brain, or near the site of infection with other
pathogens, e.g., CMV and Histoplasma spp in P16 GI.
This report is one of the few to describe therapeutic efforts to
treat granulomas in IEI patients, which have not been
standardized and were limited to small case series (18, 21, 23,
37). Unfortunately, the lack of an animal model for RuV
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during the degranulation process. These extracellular RuV can
subsequently infect macrophages and establish persistent
infection. It is also possible that RuV can infect macrophages
following efferocytosis of apoptotic infected neutrophils, a
mechanism described for Leishmania and other parasitic
infections (43). Persistently RuV-infected macrophages in the
absence of functional T-cell immunity can subsequently trigger
formation of M-type or M(n)-type granulomas. In addition to
the proposed role in the initiation of M-type granulomas,
uninfected neutrophils in a subgroup of patients can also be
mobilized within M(n)-type necrotizing RVC+ granuloma cores
leading to central necrosis. Signals triggering the development of
M(n)-type necrotizing inﬂammation are currently unknown.
The mechanisms of development of N-type and DNI-type
granulomas are less clear. Neutrophils are short-lived cells and
die by apoptosis within one day after entering tissues. Apoptosis
reduces the number of neutrophils in tissue and sends signals to
stop neutrophil inﬂux as well as to induce re-programming of
macrophages to an anti-inﬂammatory phenotype (44). Although
it has not been demonstrated for RuV, several other viral
pathogens have been shown to manipulate apoptotic and
survival pathways in neutrophils for their advantage (43).
Given that many RVC+ neutrophils accumulate in inﬂamed
internal organs or form large N-type cutaneous granulomas,
RuV may also interfere with apoptosis and extend the neutrophil
lifespan. Excessive neutrophil accumulation and delayed
apoptosis usually leads to hyperinﬂammation and, instead of
apoptosis, results in necrotic cell death followed by massive
release of proteolytic and highly cytotoxic granular proteins,

clinically improve when patients are being conditioned for bone
marrow transplantation, even before they receive their graft,
supports the importance of the bone marrow as an RuV reservoir
and the neutrophils as their vehicle. Interestingly, live RuV was
often recovered from bone marrow aspirates in infants with
congenital rubella syndrome, although RuV target cells in bone
marrow have never been determined (38). RuV persistence in
bone marrow neutrophils may impair their differentiation into
mature neutrophils as well as alter their functions. Several other
viruses have been implicated in bone marrow suppression while
persisting in erythroid precursors (parvovirus 19, dengue) or
bone marrow stromal cells (respiratory syncytial virus) (39–41).
The presented data support an evolving model where RuV
persists subclinically in neutrophil precursor cells in the bone
marrow and emerges with loss or diminution of especially T-cell
immune control, similar to JC virus (42). We propose that RuV
uses mature neutrophils as a vehicle for broad tissue
dissemination (Figure 9). RuV+ neutrophils are recruited to
the sites of inﬂammation (sterile or not sterile) where they
amplify the local inﬂammation and contribute to the
development of chronic RuV-associated inﬂammation. Which
inﬂammatory pattern develops, M-type, M(n)-type, N-type, or
DNI-type, likely depends on the microenvironment at the site of
the initial inﬂammation and the underlying IEI. We hypothesize
that RuV infection of macrophages is an intermediate step to Mtype and M(n)-type granulomas. There are two possible
mechanisms for macrophage infection. As we have shown,
viral capsid and, likely, RuV virions are localized in primary
neutrophil granules and could be released into extracellular space

FIGURE 9 | Neutrophil recruitment to inﬂamed tissues and formation of different patterns of RuV associated inﬂammation (a proposed model). After maturation, RuV
infected mature neutrophils leave the bone marrow where RuV subclinically persisted in myeloblasts before weakening of the immune control mechanisms. The
circulating neutrophils recognize signs of ongoing inﬂammation and migrate into the tissue. The location of the inﬂammatory signal and microenvironment at the site
inﬂuence the formation of a particular pattern of RuV-associated granulomas. In skin, tissue macrophages become infected with RuV either by extracellular virions
released by neutrophils or after ingesting infected neutrophils. They subsequently differentiate into epithelioid CD206+ macrophages. T cells, which are recruited to
the infected tissues but cannot eradicate RuV infection, form a structure of a mature granuloma around the RuV+ macrophage core together with migrating
monocytes and macrophages. Presence of B lymphocytes and neutrophils in the mature M-type RuV-associated granulomas is negligible. Some individuals develop
N-type necrotizing granulomas with RuV neutrophil cores, but the underlying mechanism is unclear. Inﬂux of RuV infected neutrophils into inﬂamed internal organs
and tissues attracts immune cells of the innate and adaptive immunity but does not result in the formation of compact granuloma structures. Instead, diffuse
inﬂammation pattern dominated by RuV positive neutrophils intermixed with other immune cells (DNI-type) is formed.
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thus contributing to chronic inﬂammation and organ damage
(43, 44). Resolving neutrophilic inﬂammation, therefore, may
provide clinical beneﬁt for patients with N-type and DNI-type
RuV-associated granulomas. Rare clinical responses to steroids
and TNF-a inhibitors suggest that there is an early stage where
this might be possible (Table 3). Thus, a better understanding of
the role of neutrophils in RuV associated granuloma pathologies
is critical to improving treatment options of this complication in
immunodeﬁcient patients.
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